Back to top
more

SCYNEXIS (SCYX)

(Delayed Data from NSDQ)

$2.43 USD

2.43
162,149

+0.05 (2.10%)

Updated Jun 4, 2024 04:00 PM ET

After-Market: $2.44 +0.01 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (81 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SCYX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

SCYNEXIS, Inc. [SCYX]

Reports for Purchase

Showing records 21 - 40 ( 66 total )

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 21

01/09/2020

Company Report

Pages: 7

Ibrex Shows Consistent Efficacy in Refractory Infections; Still Upside to Our Model; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 22

12/16/2019

Company Report

Pages: 7

Financing Extends Cash Runway Through Expected Mid-2021 Ibrex aVVC Approval and rVVC Phase 3 Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 23

11/11/2019

Company Report

Pages: 6

Positive Ibrex aVVC Phase 3 as We Expected

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 24

09/19/2019

Company Report

Pages: 8

Acute VVC Phase 3s Ahead of Schedule; Now Expect U.S. Data by Year-End and Global Study Early 2Q20; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 25

07/25/2019

Company Report

Pages: 6

Recurrent VVC Phase 3 Ready to Go With SPA; Funded Through Low-Risk 1H20 Acute VVC Data and Filing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 26

04/16/2019

Company Report

Pages: 5

Ibrexafungerp Increasingly Relevant in Increasingly Resistant Fungal Infections; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 10.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 27

03/19/2019

Company Report

Pages: 8

4Q18 Results; VVC Phase 3s and Potential LPAD Enabling Studies Ongoing; Pivotal Data 1H20; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 28

10/23/2018

Company Report

Pages: 7

VVC Phase 3 Plans Check Out With FDA; Consistent With Our Projections; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 29

09/07/2018

Company Report

Pages: 4

We are transferring coverage due to the departure of the covering analyst.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 30

09/07/2018

Industry Report

Pages: 3

Healthcare: Coverage Update

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 31

08/17/2018

Company Report

Pages: 7

2Q18 Results; We?re Scrapping IV for Now, But Undervalued on Oral for VVC Alone; Reiterate Buy; Lower to $4.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 32

08/10/2018

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 33

08/10/2018

Company Report

Pages: 7

2Q18 Reported; Oral SCY-078 Advances While IV Development Continues

Provider: Roth Capital Partners, Inc.

Analyst: LEBOYER R

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 34

07/12/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 35

07/11/2018

Company Report

Pages: 6

Corrected - Phase 2b Study Shows Positive Results; Dose Level For Phase 3 Selected

Provider: Roth Capital Partners, Inc.

Analyst: LEBOYER R

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 36

07/11/2018

Company Report

Pages: 8

Best-Case Phase 2b Outcome in VVC; Heading Into Phase 3

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 37

07/11/2018

Company Report

Pages: 6

Phase 2b Study Shows Positive Results; Dose Level For Phase 3 Selected

Provider: Roth Capital Partners, Inc.

Analyst: LEBOYER R

Price: 25.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 38

05/10/2018

Company Report

Pages: 5

Quarterly Update Confirms Expectations

Provider: Roth Capital Partners, Inc.

Analyst: LEBOYER R

Price: 10.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 39

05/08/2018

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: SCYNEXIS, Inc.

Industry: Medical - Drugs

Record: 40

05/07/2018

Company Report

Pages: 20

Fighting the Fungus Among Us; Assume With Buy and $5 Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 50.00

Research Provided by a Third Party